← 返回

探索基于 NK 细胞的免疫疗法靶向高级别浆液性卵巢癌的潜力

英文原题:Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas.

查看英文原题

Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas.

PubMed 2024/06/18(内容时间) Vaccines (Basel) Q2 · IF 3.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

高级别浆液性卵巢癌(HGSOC)可能由低分化的干细胞样细胞(PDSLC)和分化型肿瘤细胞组成。常规治疗无法完全清除PDSLC,导致疾病进展和肿瘤复发。已知原代NK细胞能有效裂解PDSLC,但对高分化肿瘤的细胞毒性潜力较低或极低。我们在本综述中介绍并讨论了超级NK(sNK)细胞的特征。与原代NK细胞相比,sNK细胞对PDSLC和高分化肿瘤均表现出显著更强的直接杀伤能力。此外,sNK细胞分泌显著更高水平的细胞因子,尤其是那些已知能诱导肿瘤分化的细胞因子。此外,我们提出sNK细胞与化疗的联合方案可能是消除卵巢肿瘤异质性群体最有效的策略之一;sNK细胞既能裂解PDSLC和高分化肿瘤,又能诱导PDSLC分化,并可与化疗联合用于靶向高分化肿瘤和NK诱导分化的肿瘤。

展开英文摘要原文

High-grade serous ovarian cancers (HGSOCs) likely consist of poorly differentiated stem-like cells (PDSLCs) and differentiated tumor cells. Conventional therapeutics are incapable of completely eradicating PDSLCs, contributing to disease progression and tumor relapse. Primary NK cells are known to effectively lyse PDSLCs, but they exhibit low or minimal cytotoxic potential against well-differentiated tumors.

We have introduced and discussed the characteristics of super-charged NK (sNK) cells in this review. sNK cells, in comparison to primary NK cells, exhibit a significantly higher capability for the direct killing of both PDSLCs and well-differentiated tumors.

In addition, sNK cells secrete significantly higher levels of cytokines, especially those known to induce the differentiation of tumors.

In addition, we propose that a combination of sNK and chemotherapy could be one of the most effective strategies to eliminate the heterogeneous population of ovarian tumors; sNK cells can lyse both PDSLCs and well-differentiated tumors, induce the differentiation of PDSLCs, and could be used in combination with chemotherapy to target both well-differentiated and NK-induced differentiated tumors.

论文信息

作者
Kaur K、Sanghu J、Memarzadeh S、Jewett A
单位
Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.United States
文献类型
综述
期刊
Vaccines2024 Jun 18
原文标识
PubMed 38932405 · DOI 10.3390/vaccines12060677